Skip to main content
Premium Trial:

Request an Annual Quote

Gen-Probe's Sales Up Slightly in Q2; Shares Fall

NEW YORK (GenomeWeb News) – Gen-Probe reported after the close of the market on Thursday that its overall revenues ticked up 1 percent, while its product sales rose nearly 3 percent compared with the second quarter of 2008.

The San Diego-based molecular diagnostics firm brought in revenues of $120.5 million for the three-month period ended June 30, up from $119.8 million for the second quarter of 2008.

Gen-Probe's product sales for the period were $116.8 million versus $113.7 million for the second quarter of 2008. Its collaborative research revenue was $2.2 million versus $4.7 million the year before, and its royalty and license revenue was stable at around $1.5 million.

Gen-Probe President and CEO Carl Hull said in a statement that the firm is on track in development of the "key R&D projects that we expect to boost future growth," including tests for human papillomavirus, prostate cancer, and trichomonas.

The firm said that its clinical diagnostic products sales increased 19 percent to $67.8 million from $57.2 million, and its blood screening products sales dropped by 19 percent to $45.8 million from $56.5 million.

Gen-Probe's net income declined to $19.8 million, or $.39 per share, from $24.8 million, or $.46 per share.

Its R&D expenses fell 11 percent to $26.1 million from $29.4 million, while its SG&A spending increased 27 percent to $31.9 million from $25.1 million.

Gen-Probe finished the quarter with $233.5 million in cash and cash equivalents, and another $230.7 million in marketable securities.

Following the second-quarter results, the firm lowered the top range of its guidance for 2009. It now anticipates reporting total 2009 revenues of between $490 million and $503 million, down from a range of $490 million to $510 million, and EPS of between $1.73 and $1.85, down from $1.72 to $1.90.

Herm Rosenman, Gen-Probe's senior VP of finance and CFO, said in a statement that the company expects solid growth in clinical diagnostics this year, and he expects EPS to come in slightly lower than previously predicted due to "lower-than-expected blood screening revenues in the second quarter and slower anticipated blood screening growth going forward."

In early Friday trade on the Nasdaq, Gen-Probe's shares were down 14 percent at $36.31.

The Scan

Wolf Howl Responses Offer Look at Vocal Behavior-Related Selection in Dogs

In dozens of domestic dogs listening to wolf vocalizations, researchers in Communication Biology see responses varying with age, sex, reproductive status, and a breed's evolutionary distance from wolves.

Facial Imaging-Based Genetic Diagnoses Appears to Get Boost With Three-Dimensional Approach

With data for more than 1,900 individuals affected by a range of genetic conditions, researchers compared facial phenotype-based diagnoses informed by 2D or 3D images in the European Journal of Human Genetics.

Survey Suggests Multigene Cancer Panel VUS Reporting May Vary Across Genetic Counselors

Investigators surveyed dozens of genetic counselors working in clinical or laboratory settings, uncovering attitudes around VUS reporting after multigene cancer panel testing in the Journal of Genetic Counseling.

Study Points to Tuberculosis Protection by Gaucher Disease Mutation

A mutation linked to Gaucher disease in the Ashkenazi Jewish population appears to boost Mycobacterium tuberculosis resistance in a zebrafish model of the lysosomal storage condition, a new PNAS study finds.